Please assess the completion status of the following clinical trial:

Trial Title: 42-Day Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Key Inclusion Criteria:~* 18 to 79 years of age, inclusive~* Chronic Kidney Disease (eGFR \<60 mL/min), not yet on dialysis~* Hemoglobin (Hgb) ≤ 10.5 g/dL~* Transferring saturation ≥ 20%~* Ferritin ≥ 50 ng/mL~Key Exclusion Criteria:~* Body mass index \>42~* Red blood cell transfusion within 12 weeks~* Androgen therapy within the previous 21 days prior to study dosing~* Therapy with any approved or experimental erythropoiesis stimulating agent (ESA) within the 11 weeks prior to the Screening visit~* Participants meeting the criteria of ESA resistance within the previous 4 months~* Individual doses of intravenous iron of greater than 250 mg within the past 21 days~* Aspartate aminotransferase or alanine aminotransferase \>1.8x upper limit of normal (ULN)~* Alkaline phosphatase \>2x ULN~* Total bilirubin \>1.5x ULN~* Uncontrolled hypertension~* New York Heart Association Class III or IV congestive heart failure~* Myocardial infarction, acute coronary syndrome, or stroke within 6 months prior to dosing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- AKB-6548 240 mg (Type: EXPERIMENTAL): None
- AKB-6548 370 mg (Type: EXPERIMENTAL): None
- AKB-6548 500 mg (Type: EXPERIMENTAL): None
- AKB-6548 630 mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).